Evidence map›Paper›PMID 40565351›Full record

ArticleInternational journal of molecular sciences2025

Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI.

Tannith M Noye, Parul Mittal, Zoe K Price, Annie Fewster, Georgia Williams, Tara L Pukala, Manuela Klingler-Hoffmann, Peter Hoffmann, Martin K Oehler, Noor A Lokman and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tannith M NoyeAdelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.ORCID 0000-0002-7100-0900
Parul MittalMass Spectrometry and Proteomics Group, Clinical & Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5005, Australia.ORCID 0000-0003-0139-9757
Zoe K PriceAdelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.ORCID 0000-0001-5306-3468
Annie FewsterAdelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.
Georgia WilliamsAdelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.
Tara L PukalaDiscipline of Chemistry, School of Physics, Chemistry and Earth Sciences, University of Adelaide, Adelaide, SA 5005, Australia.ORCID 0000-0001-7391-1436
Manuela Klingler-HoffmannMass Spectrometry and Proteomics Group, Clinical & Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5005, Australia.ORCID 0000-0003-2165-7813
Peter HoffmannMass Spectrometry and Proteomics Group, Clinical & Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5005, Australia.
Martin K OehlerAdelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.
Noor A LokmanAdelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.ORCID 0000-0002-2071-5308
Carmela RicciardelliAdelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.ORCID 0000-0001-7415-1854

Funding

Cancer Council SA N/AOvarian Cancer Research Foundation N/A
6 · The paper itself

Abstract

Ovarian cancer is the most lethal gynecological cancer. Up to 75% of cases are high-grade serous ovarian cancer (HGSOC) that have high chemosensitivity to first-line platinum-based therapies. However, 75% of patients will become chemoresistant following relapse. The underlying mechanism for developing resistance to chemotherapy in HGSOC is poorly understood. In this study, we employed Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Imaging (MALDI-MSI) on matching formalin-fixed paraffin-embedded (FFPE) HGSOC tissues at the time of diagnosis and following relapse with chemotherapy-resistant disease (n = 4). We identified

Indexed as

Drug Resistance, NeoplasmOvarian NeoplasmsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAgedBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedProteomicsBiomarkers, Tumorchemotherapy resistancecollagen alpha 1(XII)MALDI-MSIovarian cancerplectin

Identifiers

PMID40565351
PMCPMC12193203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.